SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is actively discussed after announcing a capital raise through a public stock offering and a non-dilutive royalty funding agreement, leading to community debate over the potential dilution versus the strategic financial runway now secured for advancing their prostate cancer drug towards anticipated regulatory submission and other pipeline assets.

Ardelyx, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing biopharmaceutical products. The firm is also involved in developing a unique and innovative platform that enables the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. The company was founded by Dominique Charmot, Peter G. Schultz, and Jean M. Frechet in October 2007 and is headquartered in Waltham, MA.

Ardelyx Inc

Ardelyx is trending following Q4 earnings that showcased robust IBSRELA revenue growth and positive cash flow, with increased operating expenses reflecting strategic investments in future pipeline and sales expansion. This, combined with extended patent protection for tenapanor until 2042 and multiple analyst price target raises, fuels community discussions about its significant undervaluation and potential as a long-term growth or acquisition target.

A project grown out of the community's love and passion for the weed culture. Launched around early 2025, $weedcoin, “Like Bitcoin but way higher,” emphasizes its alignment with cannabis culture and a laid-back vibe. Unlike other Weed communities, this project leans heavily into community engagement over technical utility, aiming to build a “stoner community” through social media presence and decentralized governance. We also aim to focus on onboarding web2 businesses and users onto web3 through the token.

Weedcoin

Weedcoin is currently trending as its community rallies around the approaching 4/20 event, underscoring a "culture first" ethos and long-term vision, while also tapping into wider conversations about cannabis rescheduling and the plant's emerging medicinal potential.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending as positive comments from PepsiCo's recent earnings and a strong management update at the CAGNY conference, coupled with analyst upgrades, fuel bullish sentiment around its market share gains and future growth. However, community discussion is intensely divided, with some attributing recent stock weakness to alleged management incompetence and deliberate manipulation to facilitate a low-cost acquisition by Pepsi.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL (GRAL) is trending due to a significant selloff following its NHS-Galleri cancer screening trial missing a primary endpoint for statistically significant reduction in late-stage cancer diagnoses, leading to analyst price target cuts. The community is divided, with bears pressing shorts on the perceived failure and cash burn, while bulls view the sharp decline as an overreaction, highlighting strong cash reserves, U.S. sales, and the test's continued potential for early detection.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy ($SWEAT) is sparking widespread community discussion and questions, with many users expressing hopeful long-term sentiment and patience for a rebound, despite the crypto's current low valuation and lack of a clear immediate catalyst.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

Rage Crypto ($RAGE) is trending due to its highly active community's unwavering conviction in its 'OG meme' status, with members relentlessly building and promoting its deep roots from the early 2000s as they aim for a significant valuation.

Starfighters Space, Inc. is engaged in the research and development of space flight, pilot training, and aeronautics programs. It operates the commercial fleet Lockhead F-104s. The company was founded by Rick Svetkoff on September 6, 2022 and is headquartered in Kennedy Space Center, FL.

Starfighters Space Inc

Starfighters Space (FJET) is experiencing robust momentum and community chatter as it prepares to ring the NYSE Opening Bell, with investors speculating on a potential short squeeze due to its low float and a broader surge of interest in the space and defense sector, amplified by recent hypersonic technology news.

Rich Sparkle Holdings Ltd. engages in the provision of financial printing and corporate services. The firm offers typesetting, proofreading, translation, design, and printing of listing documents, financial reports, fund documents, circulars, and announcements. It also delivers advisory services, such as conducting internal control assessment and environmental, social and governance performance evaluation, and other services including provision of co-working space. The company was founded in 2016 and is headquartered in Hong Kong.

Rich Sparkle Holdings Ltd.

Rich Sparkle Holdings Limited

ANPA is trending following its acquisition of TikTok icon Khaby Lame's core company and a private placement, which, alongside its IPO lock-up expiration, has ignited intense community debate about whether this "Hong Kong low float" stock represents a legitimate e-commerce growth play or a speculative pump-and-dump.

NEAR Protocol is the blockchain for AI. A high-performance, AI-native platform built to power the next generation of decentralized applications and intelligent agents. It provides the infrastructure AI needs to transact, operate, and interact across Web2 and Web3. NEAR combines three core elements: User-Owned AI, which ensures agents act in users’ best interests; Intents and Chain Abstraction, which eliminate blockchain complexity for seamless, goal-driven transactions across chains; and a sharded blockchain architecture that delivers the scalability, speed, and low-cost execution needed for real-world AI and Web3 use. This integrated stack makes NEAR the foundation for building secure, user-owned, AI-native applications at internet scale.

Near

NEAR Protocol is trending as its innovative cross-chain "Intents" technology drives broader interoperability, including recent integrations with Starknet on Solana. The community is buzzing about NEAR's strong position in the AI crypto narrative, backed by a partnership with NVIDIA and growing institutional interest highlighted by Grayscale and Bitwise filings.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Here's What Happened

Fortress Biotech (NASDAQ:FBIO) Stock Price Crosses Above 200-Day Moving Average - Time to Sell...

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving Average - Here's Why...

Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes

CI's Q4 adjusted EPS beats estimates as Evernorth growth and higher specialty volumes offset fewer medical customers and elevated costs.

Fortress Biotech (NASDAQ:FBIO) Shares Pass Above 200-Day Moving Average - What's Next?

Fortress Biotech (NASDAQ:FBIO) Shares Cross Above 200-Day Moving Average - Time to Sell...

Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums

ELV tops Q4 EPS estimates as premiums grow and Carelon revenues surge, even as medical membership slips and expenses climb.

Centene Expands Palliative Care Access in Ohio Through Tuesday Health

CNC teams up with Tuesday Health to expand palliative care in Ohio, blending in-person and virtual support.

Zacks Research Upgrades Fortress Biotech (NASDAQ:FBIO) to Strong-Buy

Zacks Research upgraded shares of Fortress Biotech from a "hold" rating to a "strong-buy" rating in a research report on Wednesday...

Research Analysts Set Expectations for FBIO FY2025 Earnings

Fortress Biotech, Inc. (NASDAQ:FBIO - Free Report) - Stock analysts at HC Wainwright issued their FY2025 earnings per share estimates for shares of Fortress Biotech in a research report issued to...

Morning Market Brief: From IP Land Grabs to FDA Greenlights, Small-Cap Innovation Takes Center Stage

<ul class="summary-bullets"><li>The FDA’s green light comes after Sentynl Therapeutics, fully owned by Zydus Lifesciences, assumed responsibility for developing and commercializing CUTX-101.</li><li>Cyprium stands to earn tiered royalties on ZYCUBO sales and up to $129 million in potential development and sales milestones from Sentynl.</li><li>Children receiving early treatment with ZYCUBO had a nearly 80% lower risk of death compared with untreated patients.&nbsp;</li></ul>Fortress Biotech, Inc. (FBIO) and its majority-owned unit, Cyprium Therapeutics, announced on Tuesday that the U.S. Food and Drug Administration (FDA) has officially approved ZYCUBO (formerly CUTX-101) for treating Menkes disease in children.The FDA’s green light comes after Sentynl Therapeutics, fully owned by Zydus Lifesciences, assumed responsibility for developing and commercializing CUTX-101 from Cyprium in December 2023.<blockquote>“The approval of ZYCUBO is a pivotal milestone for our company and patients suffering from Menkes Disease, as it is the first and only FDA-approved treatment for this rare, often fatal, pediatric disease.”-Lindsay A. Rosenwald, Chairman, President and CEO, Fortress Biotech</blockquote><h2 class="st-heading-2">Approval And Benefits</h2>The approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium. Additionally, Cyprium stands to earn tiered royalties on ZYCUBO sales and up to $129 million in potential development and sales milestones from Sentynl.Following the update,&nbsp;<a href="https://stocktwits.com/symbol/FBIO">Fortress Biotech stock</a> traded over 12% higher in Tuesday’s premarket. On Stocktwits, retail sentiment around the stock improved to ‘extremely bullish’ from ‘bullish’ territory the previous day. Message volume changed to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/Screenshot_2026_01_13_083353_png_10f3be8db7.webp" alt="FBIO’s Sentiment Meter and Message Volume as of 07:40 a.m. ET on Jan. 13, 2026 | Source: Stocktwits" width="927" height="102"><figcaption>FBIO’s Sentiment Meter and Message Volume as of 07:40 a.m. ET on Jan. 13, 2026 | Source: Stocktwits</figcaption></figure>Menkes disease is a rare genetic disorder caused by mutations in the ATP7A gene, which disrupt copper absorption and transport in infants. Without treatment, the disease can be fatal, as copper is essential for brain development.&nbsp;<h2 class="st-heading-2">ZYCUBO Efficiency&nbsp;</h2>ZYCUBO, administered as a subcutaneous injection, helps restore copper balance in the body and maintain adequate levels in patients with Menkes disease.Results supporting approval showed that children receiving early treatment with ZYCUBO had a nearly 80% lower risk of death compared with untreated patients. Median overall survival in the treated group was 177.1 months, compared with 17.6 months in the external control group.&nbsp;FBIO stock has gained over 113% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/delta-airlines-stock-falls-2026-guidance-boeing-order/cmUXI2vR44s">Delta Air Lines Stock Tumbles Despite Q4 Earnings Beat – Even A Boeing Order Failed To Lift Confidence</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Fortress Biotech logo is displayed on the screen of a tablet.

FBIO Stock Surges 12% Pre-Market After It Wins FDA Approval For Rare Pediatric Menkes Disease

FDA’s ZYCUBO approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium.

Equity

FDA’s ZYCUBO approval also includes a Rare Pediatric Disease Priority Review Voucher, which will be transferred to Cyprium.


Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. It operates through the Dermatology Product Sales and Pharmaceutical and Biotechnology Product Development segments. Its products include Ximino, Targadox, Exelderm, Ceracade, and Luxamend. The company was founded in 2006 and is headquartered in Bay Harbor Islands, FL.

Current Price	$3.48
Prev Close	$3.45
Open	$3.41
Dividend Yield	0.00%
50-Day Moving Average	$3.50
Beta	1.02
Avg. Volume	1.26M
PE Ratio	-12.89

52-Week High	$4.53
52-Week Low	$1.33
Market Capitalization	$107.08M
EPS (Annual)	-$2.69
Price to Book	1.92
Revenue Per Employee	$571,039.60

FBIO
Fortress Biotech Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest FBIO News

FBIOFortress Biotech Inc